[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hypoparathyroidism\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hypoparathyroidism":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,19,0,[8,40,82,110,135,171,204,226,247,267,294,315,340,366,387,410,436,456,481],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100054159","phase-3-a-study-to-investigate-canvuparatide-compared-with-placebo-in-adult-patients-with-hypoparathyroidism-100054159",false,"NCT07699471","A Study to Investigate Canvuparatide Compared With Placebo in Adult Patients With Hypoparathyroidism","A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Followed by an Open-Label Extension to Evaluate the Safety and Efficacy of Canvuparatide (MBX 2109) in Adult Patients With Hypoparathyroidism","Key Inclusion Criteria:\n\n1. Is an adult ≥18 years of age.\n2. Has a documented diagnosis of post-surgical, chronic HypoPT or genetic, idiopathic, or autoimmune HypoPT for at least 12 months prior to screening.\n3. Intact PTH level below the median value of the normal range\n4. Minimum requirement for a dose of calcitriol ≥0.5 μg\u002Fday, or alfacalcidol ≥1.0 μg\u002Fday and (elemental) calcium ≥1000 mg\u002Fday for at least 12 weeks prior to screening. In addition, the doses of calcitriol, or alfacalcidol, and calcium should be stable for at least 3 weeks prior to screening.\n5. Two (2) consecutive measurements of albumin-adjusted serum calcium at least 1 week apart within the range of 7.8 to 9.4 mg\u002FdL (1.95 to 2.35 mmol\u002FL).\n\nKey Exclusion Criteria:\n\n1. Has a known history of pseudohypoparathyroidism\n2. Clinically significant abnormal hematology, clinical chemistry, or coagulation.\n3. Any disease that might affect calcium metabolism or calcium-phosphate homeostasis or PTH levels other than HypoPT, such as active endogenous hyperthyroidism;\n4. Use of therapies affecting the calcium metabolism within 4 weeks prior to randomization\n5. PTH or PTH-related protein drugs such as PTH(1-84) and PTH(1-34) within 5 weeks prior to screening.","ALL","18 Years",{"count":19,"type":20},160,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","The purpose of this study is to investigate the efficacy and safety of canvuparatide administered as a once-weekly (QW) treatment to adult study participants with hypoparathyroidism (HypoPT).",[26],"Hypoparathyroidism","RECRUITING","2026-07-07",{"date":30,"type":31},"2026-07-13","ACTUAL",{"date":33,"type":20},"2026-08",{"date":35,"type":20},"2029-08",{"name":37,"class":38},"MBX Biosciences","INDUSTRY",2,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":21,"phases":49,"briefSummary":51,"conditions":52,"keywords":58,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":76,"leadSponsor":78,"locationsCount":81},"100640349","niraf-guided-parathyroid-identification-during-thyroidectomy-100640349","NCT07617584","NIRAF-Guided Parathyroid Identification During Thyroidectomy","Near-Infrared Autofluorescence-Guided Parathyroid Identification During Thyroidectomy","Inclusion Criteria:\n\n* Age 18 years or older.\n* For Component A: planned thyroidectomy of any extent with an intact specimen available for ex vivo evaluation.\n* For Component B: planned total or completion thyroidectomy.\n* Ability to provide written informed consent before surgery.\n* Willingness to comply with routine postoperative laboratory testing and follow-up when feasible.\n\nExclusion Criteria:\n\n* Known pre-existing hypoparathyroidism or prior parathyroid surgery.\n* Severe chronic kidney disease or end-stage renal disease expected to substantially confound calcium and parathyroid hormone interpretation, as defined by the site investigator.\n* Pregnancy.\n* For Component B only: gross nodal disease or a surgical plan requiring extensive nodal packet dissection in the current study phase.\n* Any condition that, in the judgment of the investigator, would make participation unsafe or compromise protocol adherence.",{"count":48,"type":20},280,[50],"NA","This is a single-site, two-component prospective study evaluating whether near-infrared autofluorescence (NIRAF) imaging can improve intraoperative identification of parathyroid glands during thyroidectomy and reduce postoperative hypocalcemia.\n\nThe investigational platform is a modified wearable stereoscopic goggle system configured for label-free NIRAF imaging. Parathyroid tissue is excited with near-infrared light at approximately 780 nm and emits autofluorescence centered near 800 nm. No injected dye or external contrast agent is used. The goggles are used only during a brief mapping interval after thyroid exposure and for ex vivo interrogation of the resected thyroid specimen.\n\nComponent A is a prospective observational run-in validation cohort of 30 adults undergoing thyroidectomy of any extent. NIRAF-positive foci on the intact thyroidectomy specimen are suture-marked and correlated with targeted pathology.\n\nComponent B is a randomized clinical study of 250 adults undergoing total or completion thyroidectomy. Participants are randomized 1:1 to standard surgery or standard surgery plus brief in vivo NIRAF mapping, ex vivo specimen interrogation, and rescue autotransplantation when indicated. The primary outcome for Component B is transient biochemical hypocalcemia on postoperative day 1, defined using albumin-corrected serum calcium.",[53,26,54,55,56,57],"Hypocalcemia","Thyroid Diseases","Goiter, Nodular","Thyroid Nodule","Thyroidectomy",[59,60,61,62,57,63,64,65,66,67,68,69,70],"Near-Infrared Autofluorescence","NIRAF","Parathyroid Identification","Parathyroid Preservation","Completion Thyroidectomy","Total Thyroidectomy","Postoperative Hypocalcemia","Intact Parathyroid Hormone","iPTH","Rescue Autotransplantation","Wearable Imaging","Post-thyroidectomy hypocalcemia","NOT_YET_RECRUITING","2026-05-29",{"date":74,"type":31},"2026-06-01",{"date":74,"type":20},{"date":77,"type":20},"2029-12-01",{"name":79,"class":80},"Ss. Cyril and Methodius University of Skopje","OTHER",1,{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":87,"acronym":88,"eligibilityCriteria":89,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":21,"phases":93,"briefSummary":95,"conditions":96,"keywords":97,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":81},"100608122","early-phase-1-efficacy-and-safety-of-xh02-for-the-treatment-of-hypoparathyroidism-100608122","NCT07197450","Efficacy and Safety of XH02 for the Treatment of Hypoparathyroidism","Efficacy and Safety of mRNA Drug XH02 in the Treatment of Adult Hypoparathyroidism","XH02","Inclusion Criteria:\n\n* Age 18 to 65 years (inclusive), male or female.\n* Documented history of post-surgical chronic HP or autoimmune, genetic, or idiopathic HP for at least 26 weeks. Diagnosis of HP is confirmed based on a history of hypocalcemia accompanied by an inappropriately low serum PTH level (below the upper limit of the normal range of the local laboratory). \\* Note: If a subject lacks documented diagnosis of chronic HP but has exhibited hypocalcemia accompanied by an inappropriately low serum PTH level for at least 26 weeks prior to screening, and is judged by the investigator to meet the diagnostic criteria for chronic HP, they will be considered eligible for this criterion.\n* Poorly controlled or intolerant to conventional therapy (calcium and active vitamin D).\n* Body Mass Index (BMI) of 17 to 40 kg\u002Fm² (inclusive) at screening.\n* If aged ≤ 25 years, radiological evidence of closed epiphyses based on X-ray of the non-dominant hand (wrist and palm).\n\nExclusion Criteria:\n\n* Impaired PTH response (pseudohypoparathyroidism), characterized by PTH resistance and elevated PTH levels in the presence of hypocalcemia.\n* History of allergic predisposition, or known allergy to the investigational drug or polyethylene glycol (PEG)-containing medications.\n* Any disease other than HP that may affect calcium metabolism, calcium-phosphate homeostasis, or PTH levels, such as: active hyperthyroidism; Paget's disease of bone; severe hypomagnesemia; type 1 diabetes mellitus or poorly controlled type 2 diabetes (HbA1c \\>9%; HbA1c results from within 12 weeks prior to screening are acceptable); severe and chronic liver or kidney disease; Cushing's syndrome; multiple myeloma; active pancreatitis; malnutrition; rickets; recent prolonged immobilization; active malignancy (except for low-risk, well-differentiated thyroid cancer or non-melanoma skin cancer); active hyperparathyroidism; history of parathyroid carcinoma within 5 years prior to screening; acromegaly; or multiple endocrine neoplasia syndromes.\n* History of vaccination within 4 weeks prior to enrollment, or planned vaccination during the study period.\n* Pregnant or lactating women.\n* Patients with high-risk thyroid cancer requiring TSH suppression \\\u003C0.2 mIU\u002FL within the past 2 years, or patients with a history of malignancy.\n* Requirement for long-term use of the following medications: diuretics, phosphate binders (except calcium supplements), digoxin, lithium, methotrexate, biotin \\>30 μg\u002Fday, or systemic corticosteroids (except as replacement therapy). Patients requiring long-term use of hormones or immunosuppressants (e.g., for rheumatologic\u002Fautoimmune diseases) are excluded. \\*Note: Subjects who can discontinue these medications for the study may be enrolled, provided the medications are stopped for at least 5.5 half-lives prior to blood sampling at Visit 1. Biotin must be stopped for at least 1 day prior to blood sampling during the screening period. These medications are prohibited throughout the entire study.\\*\n* Use of PTH-like drugs (whether commercially available or obtained through participation in a clinical trial), including PTH(1-84), PTH(1-34), other N-terminal fragments or analogs of PTH, or PTH-related protein, within 4 weeks prior to screening.\n* Participation in any other interventional trial involving an investigational drug or device within 8 weeks prior to screening, or within 5.5 half-lives of the administered drug from the previous trial (whichever is longer).\n* Uncontrolled hypertension at baseline, OR a history of the following cardiovascular and cerebrovascular diseases: (1) Unstable angina; (2) Drug-requiring or severe arrhythmia; (3) Myocardial infarction; (4) Class III or higher heart failure (NYHA classification), or second-degree or higher atrioventricular block; (5) Cerebral infarction (except lacunar infarction), cerebral hemorrhage, or related diseases.\n* Increased risk of osteosarcoma, such as Paget's disease of bone or unexplained elevated alkaline phosphatase; hereditary disorders predisposing to osteosarcoma; or patients who have received extensive external beam radiation therapy or implant radiation involving the skeleton.\n* Clinically significant abnormal laboratory findings at screening, including any of the following:\n\nHematology: Neutrophil count (NEUT#) \\\u003C1.5 × 10⁹\u002FL; Platelet count (PLT) \\\u003C90 × 10⁹\u002FL; Hemoglobin (Hb) \\\u003C90 g\u002FL; Eosinophil count (EOS#) \\>0.5 × 10⁹\u002FL.\n\nLiver and Renal Function: Total bilirubin, Alanine Aminotransferase (ALT), or Aspartate Aminotransferase (AST) above the normal range; estimated Glomerular Filtration Rate (eGFR) \\\u003C60 mL\u002Fmin\u002F1.73m².\n\n* Any medical or other condition that, in the judgment of the Investigator, may affect the conduct of the study, interfere with the interpretation of study results, or pose an increased risk to the subject or the study.","65 Years",{"count":92,"type":20},6,[94],"EARLY_PHASE1","This study aims to evaluate the safety and efficacy of a novel PTH replacement therapy drug in patients with hypoparathyroidism. The drug is an mRNA drug which will be translated into PTH after intravenous administration, to achieve the therapeutic effect.",[26],[98,99,100],"hypoparathyroidism","PTH","mRNA","2026-05-19",{"date":103,"type":31},"2026-05-22",{"date":105,"type":31},"2025-05-20",{"date":107,"type":20},"2026-07-30",{"name":109,"class":80},"Peking Union Medical College Hospital",{"id":111,"slug":112,"hasResults":11,"nctId":113,"briefTitle":114,"officialTitle":115,"acronym":4,"eligibilityCriteria":116,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":117,"enrollmentInfo":118,"targetDuration":4,"studyType":21,"phases":120,"briefSummary":122,"conditions":123,"keywords":124,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":127,"lastUpdatePostDateStruct":128,"startDateStruct":130,"completionDateStruct":132,"leadSponsor":134,"locationsCount":81},"100634484","phase-2-a-cohort-study-on-the-safety-and-efficacy-of-xh-02-in-treating-hypoparathyroidism-100634484","NCT07540286","A Cohort Study on the Safety and Efficacy of XH-02 in Treating Hypoparathyroidism","An Expanded Cohort Study on the Safety and Efficacy of mRNA Nucleic Acid Drug XH-02 in Treating Adult Hypoparathyroidism","Inclusion Criteria:\n\n1. Age ≥18 years, both males and females eligible;\n2. History of postoperative chronic HP or autoimmune, genetic, or idiopathic HP for at least 26 weeks. The diagnosis of HP is established based on the presence of inappropriately low serum PTH levels concurrent with hypocalcemia in the past.\n3. Poorly controlled or intolerant to conventional treatment (calcium and vitamin D) for hypoparathyroidism;\n4. BMI 17-40 kg\u002Fm² (inclusive) at screening;\n5. If age ≤25 years, radiographic evidence of epiphyseal closure based on X-ray results of the wrist and palm of the non-dominant hand.\n\nExclusion Criteria:\n\n1. Impaired PTH response (pseudohypoparathyroidism), characterized by PTH resistance and elevated PTH levels in the presence of hypocalcemia;\n2. Allergic constitution, or allergy to the investigational drug or polyethylene glycol (PEG)-based drugs;\n3. Any disease other than HP that may affect calcium metabolism, calcium-phosphorus homeostasis, or PTH levels, such as active hyperthyroidism; Paget's disease of bone; severe hypomagnesemia; type 1 diabetes mellitus or poorly controlled type 2 diabetes mellitus (HbA1C \\>9%; HbA1C test results from blood samples collected within 12 weeks prior to screening are acceptable); severe and chronic liver or kidney disease; Cushing's syndrome; multiple myeloma; active pancreatitis; malnutrition; rickets; recent prolonged immobilization; active malignancy (except for low-risk well-differentiated thyroid cancer or non-melanoma skin cancer); active hyperparathyroidism; parathyroid carcinoma occurring within 5 years prior to screening; acromegaly; or multiple endocrine neoplasia;\n4. Pregnant or breastfeeding women;\n5. Male partners with female partners planning to become pregnant, or partners of childbearing potential who are unwilling to use adequate contraceptive methods during the study period;\n6. Patients with high-risk thyroid cancer requiring TSH suppression to \\\u003C0.2 mIU\u002FL within 2 years, or those with a history of tumors;\n7. Use of loop diuretics, phosphate binders (except calcium supplements), digoxin, lithium, methotrexate, biotin \\>30 mcg\u002Fday, or systemic corticosteroids (except as replacement therapy);\n8. Use of PTH-like drugs (whether commercially available or obtained through participation in clinical trials), including PTH(1-84), PTH(1-34), or other N-terminal fragments or analogs of PTH, or PTH-related protein within 4 weeks prior to screening;\n9. Participation in any other interventional trial receiving investigational drugs or devices within 8 weeks prior to screening, or still within 5.5 half-lives of the investigational drug from the trial in which they participated;\n10. Presence of uncontrolled hypertension at baseline, or a history of the following cardiovascular or cerebrovascular diseases, including: (1) unstable angina; (2) cardiac arrhythmias requiring medication or severe arrhythmias; (3) myocardial infarction; (4) heart failure class III or higher (NYHA classification), second-degree or higher atrioventricular block; (5) cerebral infarction (excluding lacunar infarction), cerebral hemorrhage, or other such diseases;\n11. Increased risk of osteosarcoma, such as having Paget's disease of bone or unexplained elevated alkaline phosphatase, having genetic disorders predisposing to osteosarcoma, or having a prior history of extensive external beam or implant radiation therapy involving bone;\n12. Disease processes that adversely affect gastrointestinal absorption, including but not limited to short bowel syndrome, significant small bowel resection, gastric bypass surgery, tropical sprue, active celiac disease, active ulcerative colitis, active Crohn's disease, gastroparesis, and autoimmune regulator gene mutations associated with malabsorption;\n13. Any medical or other condition that, in the investigator's judgment, may affect the conduct of the study, interfere with the study results, or increase the risk to the subject\u002Fstudy.","90 Years",{"count":119,"type":20},60,[121],"PHASE2","XH-02 is an mRNA nucleic acid drug that expresses PTH in the body following intravenous or subcutaneous injection, providing PTH replacement therapy for patients with hypoparathyroidism. Previous clinical studies have demonstrated the safety of subcutaneously administered XH-02 in several patients with hypoparathyroidism and have yielded clear efficacy results. This study aims to further validate the safety and efficacy of subcutaneously injected XH-02 in the treatment of hypoparathyroidism in a expanded cohort.",[26],[98,125,126],"XH-02","mRNA drug","2026-05-13",{"date":129,"type":31},"2026-05-18",{"date":131,"type":31},"2026-04-13",{"date":133,"type":20},"2030-07-30",{"name":109,"class":80},{"id":136,"slug":137,"hasResults":11,"nctId":138,"briefTitle":139,"officialTitle":139,"acronym":140,"eligibilityCriteria":141,"healthyVolunteers":142,"sex":16,"minAge":17,"maxAge":143,"enrollmentInfo":144,"targetDuration":4,"studyType":146,"phases":4,"briefSummary":147,"conditions":148,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":81},"100599366","routine-validation-and-reproducibility-testing-of-laboratory-assays-and-research-techniques-used-for-endocrine-cardiometabolic-and-musculoskeletal-disorder-research-vald-100599366","NCT07083557","Routine Validation and Reproducibility Testing of Laboratory Assays and Research Techniques Used for Endocrine, Cardiometabolic, and Musculoskeletal Disorder Research (VALD)","VALD","Inclusion Criteria:\n\n* ≥18 and ≤100 years of age\n* body mass index ≥16.0 and ≤60 kg\u002Fm2\n\nExclusion Criteria:\n\n* \\\u003C18 and \\>100 years of age\n* body mass index \\\u003C16.0 or \\>60 kg\u002Fm2\n* allergies, intolerances, or dietary restrictions to meal ingredients, vegans or vegetarians\n* use of medications or dietary supplements (e.g., anti-inflammatories, immune modulators, etc) that could interfere with the particular assay\u002Ftechniques being evaluated\n* engaged in regular structured exercise \\>150 min per week unless needed for validation of the assay\u002Ftechnique being evaluated\n* significant organ system dysfunction or diseases, except those that are sought for validation of the assay\u002Ftechnique being evaluated\n* alcohol use disorder as defined by the National Institute of Alcohol Abuse and Alcoholism or use of controlled substances unless alcohol use disorder is required for validation of the assay\u002Ftechnique being evaluated\n* pregnant women, persons who smoke, prisoners, and inability to grant voluntary informed consent.",true,"100 Years",{"count":145,"type":20},100,"OBSERVATIONAL","The purpose of this research study is to validate (check the accuracy of) laboratory assays, intravenous catheter insertion, and equipment or devices and their reproducibility, which is necessary to perform high quality research on chronic diseases, nutrition, and metabolism (the process by which a substance is handled in the body) at the University of Missouri. As technology changes and uses new testing methods, it is necessary to compare results from old tests, equipment and devices and new tests, equipment, or devices and the reproducibility of these measurements to make sure the results are accurate. Reproducibility means performing the same test more than once to see if the same results can be achieved each time. This study will look at the validation and reproducibility of tests and laboratory assays in participants who are healthy or affected by relevant endocrine, cardiometabolic, and musculoskeletal disorders.",[149,150,151,152,153,154,155,156,26,157,158,159,160,161],"Obesity and Obesity-related Medical Conditions","Diabetes","Atherosclerotic Disease","Heart Failure","MASH","Sarcopenia","Osteoporosis","Hyperparathyroidism","Ischemic Heart Disease","Cystic Fibrosis (CF)","Chronic Kidney Disease(CKD)","Osteopenia","Cachexia","2026-05-05",{"date":164,"type":31},"2026-05-07",{"date":166,"type":20},"2027-01-01",{"date":168,"type":20},"2030-07-01",{"name":170,"class":80},"Bettina Mittendorfer",{"id":172,"slug":173,"hasResults":11,"nctId":174,"briefTitle":175,"officialTitle":176,"acronym":177,"eligibilityCriteria":178,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":179,"targetDuration":4,"studyType":21,"phases":181,"briefSummary":182,"conditions":183,"keywords":186,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":194,"lastUpdatePostDateStruct":195,"startDateStruct":197,"completionDateStruct":199,"leadSponsor":201,"locationsCount":203},"100599246","phase-3-a-phase-3-randomized-clinical-trial-to-investigate-the-safety-and-efficacy-of-palopegteriparatide-at-doses-greater-than-30-gday-in-adult-participants-with-hypoparathyroidism-100599246","NCT07081997","A Phase 3 Randomized Clinical Trial to Investigate the Safety and Efficacy of Palopegteriparatide at Doses Greater Than 30 μg\u002FDay in Adult Participants With Hypoparathyroidism","A Phase 3, Multicenter, Randomized, Open-Label Trial Investigating the Safety, Tolerability and Efficacy of Palopegteriparatide Administered Subcutaneously Daily at Doses Greater Than 30 μg\u002FDay in Adult Participants With Hypoparathyroidism","PaTHway60","Inclusion criteria:\n\n1. Males and females, ≥18 years of age at the time of providing informed consent\n2. Participants with postsurgical chronic hypoparathyroidism (HP), or auto-immune, genetic, or idiopathic HP, for at least 26 weeks\n3. Receiving doses of palopegteriparatide at or above 30 µg\u002Fday\n\n   For individuals receiving 30 µg\u002Fday: evidence that dose is insufficient to keep serum calcium in the normal range, defined as:\n\n   Documented hypocalcemia within 12 weeks prior to Screening; and\u002For Standing dose of calcitriol ≥0.25 μg\u002Fday, and \u002F or (elemental) calcium ≥1500 mg\u002Fday (e.g., calcium citrate, calcium carbonate etc.) for at least 4 weeks prior to Screening\n\n   For individuals receiving 33 µg\u002Fday or greater: no requirement for documented hypocalcemia or minimum doses of calcitriol or elemental calcium\n4. Confirmation of laboratory parameters (Central and Local) within 2 weeks of screening visit and prior to randomization:\n\n25(OH) vitamin D levels of 20 - 80 ng\u002FmL (49 - 200 nmol\u002FL) and Magnesium level in the normal range, or just below the normal range i.e.: ≥1.3 mg\u002FdL (≥0.53 mmol\u002FL) and Albumin-adjusted or ionized sCa level in the normal range or just below the normal range\n\n* Albumin-adjusted sCa 7.8 - 10.6 mg\u002FdL (or 1.95 - 2.64 mmol\u002FL)\n* Ionized sCa 4.40 - 5.29 mg\u002FdL (1.10 - 1.32 mmol\u002FL)\n\n  5\\. BMI 17- 40 kg\u002Fm2 at Screening\n\n  6\\. If ≤25 years of age, radiological evidence of epiphyseal closure based on locally interpreted X-ray of non-dominant wrist and hand\n\n  7\\. eGFR ≥30 mL\u002Fmin\u002F1.73 m2 during Screening using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula\n\nExclusion criteria\n\n1. Impaired responsiveness to PTH (pseudohypoparathyroidism), which is characterized as PTH-resistance, with elevated PTH levels in the setting of hypocalcemia\n2. Any disease that might affect calcium metabolism or calcium-phosphate homeostasis or PTH levels other than HP\n3. Use of loop diuretics, phosphate binders (other than calcium supplements), digoxin, lithium, methotrexate, biotin \\>30 µg\u002Fday, or systemic corticosteroids (other than as replacement therapy)\n4. Use of thiazide diuretic within 4 weeks prior to the 24-hour urine collection scheduled to occur within 1 week prior to Visit 1\n5. Use of PTH-like drugs other than palopegteriparatide (whether commercially available or through participation in an investigational trial), including PTH(1-34), or other N-terminal fragments, analogs of PTH or PTH-related protein, or PTH1R biased agonists within 4 weeks prior to Screening\n6. Use of drugs known to influence calcium and bone metabolism within 12 weeks prior to Screening\n7. Use of osteoporosis therapies other than bisphosponate known to influence calcium and bone metabolism within 2 years prior to Screening. Note: use of bisphosphonate (oral or intravenous \\[IV\\] is not exclusionary\n8. Non-hypocalcemic seizure disorder with occurrence of a seizure within 26 weeks prior to Screening.\n9. Increased risk for osteosarcoma\n10. Women who are pregnant, intend to become pregnant, or are lactating\n11. Male who has a female partner who intends to become pregnant or is of childbearing potential and is unwilling to use adequate contraceptive methods during the trial\n12. Diagnosed drug or alcohol dependence within 3 years prior to Screening\n13. Chronic or severe cardiac disease within 26 weeks prior to Screening\n14. Cerebrovascular accident within 5 years prior to Screening.\n15. Within 26 weeks prior to Screening: acute colic due to nephrolithiasis, or acute gout\n16. Participation in any other interventional trial in which receipt of investigational drug or device other than palopegteriparatide occurred within 8 weeks (or within 5.5 times the half-life of the investigational drug) (whichever comes first) prior to Screening.\n17. Known allergy or sensitivity to PTH or any of the excipients \\[metacresol, mannitol, succinic acid, NaOH\u002F(HCl)\\] of the investigational product",{"count":180,"type":20},36,[23],"This trial has a duration of 78 weeks and will include adult participants already on treatment with palopegteriparatide at doses at or greater than 30 mcg\u002Fday. All participants will receive subcutaneous palopegteriparatide during the trial and will be individually and progressively titrated to an optimal dose at pre-specified dose levels. The primary purpose of the trial is to provide additional evidence of treatment effect and safety of palopegteriparatide at doses greater than 30 mcg\u002Fday in adults with hypoparathyroidism. The trial will be conducted in the US.",[26,184,185],"Endocrine System Diseases","Parathyroid Diseases",[26,187,188,189,190,191,192,193],"Parathyroid Hormone","TransCon PTH","PTH(1-34)","Prodrug","Sustained Release","Parathyroid Hormone Replacement Therapy","Palopegteriparatide","2026-05-01",{"date":196,"type":31},"2026-05-04",{"date":198,"type":31},"2026-04-16",{"date":200,"type":20},"2028-06",{"name":202,"class":38},"Ascendis Pharma Bone Diseases A\u002FS",3,{"id":205,"slug":206,"hasResults":11,"nctId":207,"briefTitle":208,"officialTitle":208,"acronym":4,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":210,"minAge":17,"maxAge":211,"enrollmentInfo":212,"targetDuration":214,"studyType":146,"phases":4,"briefSummary":215,"conditions":216,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":81},"100613288","a-study-to-assess-the-amount-of-palopegteriparatide-in-breast-milk-of-lactating-females-requiring-yorvipath-palopegteriparatide-100613288","NCT07264634","A Study to Assess the Amount of Palopegteriparatide in Breast Milk of Lactating Females Requiring YORVIPATH® (Palopegteriparatide)","Inclusion Criteria:\n\n* 1\\. Lactating female participants 18 years of age or older treated with YORVIPATH as part of their usual medical care and who have chosen to breastfeed. Note: The participant must have been taking YORVIPATH for a minimum of 14 days prior to sample collection.\n* 2\\. The major source of infant nutrition must be breast milk (Note: Only one supplemental bottle of no more than up to 8 oz of formula per day will be allowed during the 14 days before start of the study).\n* 3\\. Daily dose of YORVIPATH administered within the last 14 days has been stable.\n* 4\\. Participants recruited from other sources must enroll in the Pregnancy Registry before being allowed to participate in the Lactation Study.\n* 5\\. Written consent or eConsent obtained.\n\nExclusion Criteria:\n\n* 1\\. Presence of any medical condition that, in the opinion of the investigator, may impair the ability to breastfeed during this study, including but not limited to mastitis and nipple malformation","FEMALE","50 Years",{"count":213,"type":20},10,"6 Days","This is an observational, opportunistic lactation study to be conducted in lactating female participants who are currently receiving therapeutic doses of YORVIPATH as part of their usual care and who have chosen to breastfeed their infant(s). The potential transfer of palopegteriparatide into breast milk will be assessed.",[26],"2026-04-15",{"date":219,"type":31},"2026-04-17",{"date":221,"type":31},"2026-03-19",{"date":223,"type":20},"2028-01",{"name":225,"class":38},"Ascendis Pharma A\u002FS",{"id":227,"slug":228,"hasResults":11,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":4,"eligibilityCriteria":232,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":90,"enrollmentInfo":233,"targetDuration":4,"studyType":21,"phases":235,"briefSummary":237,"conditions":238,"keywords":239,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":242,"completionDateStruct":244,"leadSponsor":246,"locationsCount":81},"100633747","phase-1-efficacy-and-safety-of-subcutaneous-injection-of-xh-02-in-the-treatment-of-adult-hypoparathyroidism-100633747","NCT07530705","Efficacy and Safety of Subcutaneous Injection of XH-02 in the Treatment of Adult Hypoparathyroidism","Efficacy and Safety of Subcutaneous Injection of mRNA Nucleic Acid Drug XH-02 in the Treatment of Adult Hypoparathyroidism","Inclusion Criteria:\n\n1. Aged 18-65 years (inclusive of 18 and 65), male or female.\n2. A history of postoperative chronic hypoparathyroidism (HP) or autoimmune, genetic, or idiopathic HP for at least 26 weeks. HP is confirmed based on a previous occurrence of hypocalcemia accompanied by an inappropriately low serum parathyroid hormone (PTH) level (below the upper limit of the local laboratory's normal range). Note: If the subject does not have a documented diagnosis of chronic HP but has experienced hypocalcemia accompanied by an inappropriately low serum PTH level for at least 26 weeks prior to screening, and the investigator determines that the diagnosis of chronic HP is met, this criterion is considered fulfilled.\n3. Inadequate control of hypoparathyroidism with conventional treatment (calcium and vitamin D) or intolerance to such treatment.\n4. At screening, Body Mass Index (BMI) of 17-40 kg\u002Fm² (inclusive).\n5. If aged ≤25 years, radiographic evidence of epiphyseal closure based on X-ray examination of the wrist and hand of the non-dominant hand.\n\nExclusion Criteria:\n\n1. Impaired response to PTH (pseudohypoparathyroidism), characterized by resistance to PTH and elevated PTH levels during hypocalcemia.\n2. Known allergies, or a history of allergy to the investigational drug or polyethylene glycol (PEG).\n3. Any disease other than HP that may affect calcium metabolism, calcium-phosphorus homeostasis, or PTH levels, such as active hyperthyroidism; Paget's disease of bone; severe hypomagnesemia; Type 1 diabetes mellitus or poorly controlled Type 2 diabetes mellitus (HbA1C \\>9%, HbA1C test results from blood samples collected within 12 weeks prior to screening are acceptable); severe and chronic liver or kidney disease; Cushing's syndrome; multiple myeloma; active pancreatitis; malnutrition; rickets; recent prolonged immobilization; active malignancy (except for low-risk well-differentiated thyroid cancer or non-melanoma skin cancer); active hyperparathyroidism; history of parathyroid cancer within 5 years prior to screening; acromegaly; or multiple endocrine neoplasia.\n4. History of vaccination within 4 weeks prior to enrollment, or planned vaccination during the study period.\n5. Women who are pregnant or breastfeeding.\n6. Patients with high-risk thyroid cancer requiring TSH suppression to \\\u003C0.2 mIU\u002FL within the past 2 years, or those with a history of malignancy.\n7. Subjects requiring long-term use of diuretics, phosphate binders (except calcium supplements), digoxin, lithium, methotrexate, biotin \\>30 μg\u002Fday, or systemic corticosteroids (except as replacement therapy). Patients requiring long-term use of hormones or immunosuppressants (e.g., for rheumatic or autoimmune diseases) will not be enrolled in this study. Note: Subjects who can discontinue these medications during the study may be enrolled, but they must be discontinued for at least 5.5 half-lives prior to Visit 1 blood sample collection. Biotin must be discontinued for at least 1 day prior to screening blood sample collection. These medications are prohibited throughout the study.\n8. Use of PTH-like drugs (either commercially available or obtained through participation in a clinical trial), including PTH (1-84), PTH (1-34), or other N-terminal fragments or analogs of PTH, or PTH-related protein, within 4 weeks prior to screening.\n9. Participation in any other interventional trial and receipt of investigational drug or device within 8 weeks prior to screening, or still within 5.5 half-lives of the drug from a previously participated trial.\n10. Presence of uncontrolled hypertension at baseline, or a history of the following cardiovascular or cerebrovascular diseases, including: (1) Unstable angina; (2) Arrhythmia requiring medication or severe arrhythmia; (3) Myocardial infarction; (4) Class III or higher heart failure (per NYHA classification), second-degree or higher atrioventricular block; (5) Cerebral infarction (except lacunar infarction), cerebral hemorrhage, or other such conditions.\n11. Increased risk of osteosarcoma, for example, having Paget's disease of bone or unexplained elevated alkaline phosphatase, genetic disorders predisposing to osteosarcoma, or previous exposure to high-dose external beam radiation or implant radiotherapy to the skeleton.\n12. Abnormal laboratory test results meeting any of the following criteria: Blood routine: Neutrophil count (NEUT#) \\\u003C1.5×10⁹\u002FL; Platelet count (PLT) \\\u003C90×10⁹\u002FL; Hemoglobin (Hb) \\\u003C90g\u002FL; Eosinophil count (EOS#) \\>0.5×10⁹\u002FL. Liver and kidney function: Total bilirubin or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) exceeding the normal range; eGFR \\\u003C60 ml\u002Fmin\u002F1.73m².\n13. Any other medical or other condition that, in the investigator's judgment, might affect the conduct of the study or interfere with the study results, or might increase the risk to the subject.",{"count":234,"type":20},15,[236,121],"PHASE1","XH-02 is an mRNA nucleic acid drug that expresses PTH in the body following intravenous or subcutaneous injection, providing PTH replacement therapy for patients with hypoparathyroidism. Animal studies have shown pharmacodynamic effects of XH-02, with a favorable safety profile. A clinical study of intravenously administered XH-02 has been completed in patients with hypoparathyroidism, yielding clear pharmacodynamic results and demonstrating good safety. This study aims to evaluate the safety and efficacy of subcutaneously injected XH-02 in patients with hypoparathyroidism.",[26],[98,125,100],"2026-04-08",{"date":217,"type":31},{"date":243,"type":31},"2025-11-17",{"date":245,"type":20},"2026-06-30",{"name":109,"class":80},{"id":248,"slug":249,"hasResults":11,"nctId":250,"briefTitle":251,"officialTitle":251,"acronym":4,"eligibilityCriteria":252,"healthyVolunteers":11,"sex":210,"minAge":253,"maxAge":211,"enrollmentInfo":254,"targetDuration":256,"studyType":146,"phases":4,"briefSummary":257,"conditions":258,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":259,"lastUpdatePostDateStruct":260,"startDateStruct":262,"completionDateStruct":264,"leadSponsor":266,"locationsCount":81},"100619505","a-global-pregnancy-registry-to-assess-maternal-fetal-and-infant-outcomes-following-exposure-to-yorvipath-palopegteriparatide-during-pregnancy-and-breastfeeding-100619505","NCT07345494","A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding","Inclusion Criteria:\n\n* Participants aged 15 to 50 years\n* Participants with exposure to at least one dose of YORVIPATH at any time within 15 days prior to conception and\u002For during pregnancy. The timeframe of 15 days prior to conception is calculated based on 5 times the YORVIPATH half life of \\~ 60 hours\n* Participants providing written informed consent, verbal consent, or eConsent (depending on country regulations) and a Medical Release of Information. For adolescents under the age of majority, verbal or written informed assent by the pregnant minor (where applicable) and verbal or written informed consent by the parent\u002Flegal guardian will be obtained.\n\nExclusion Criteria:\n\n* Pregnancies in which only the male partner is exposed to at least one dose of YORVIPATH.","15 Years",{"count":255,"type":20},50,"21 Months","The purpose of this registry study is to collect both prospective and retrospective data in women exposed to palopegteriparatide during pregnancy to assess risk of pregnancy and maternal complications, and adverse effects on the developing fetus, neonate, and infant and to assess infant outcomes through at least the first year of life.",[26],"2026-02-26",{"date":261,"type":31},"2026-03-02",{"date":263,"type":31},"2026-02-18",{"date":265,"type":20},"2036-01",{"name":225,"class":38},{"id":268,"slug":269,"hasResults":11,"nctId":270,"briefTitle":271,"officialTitle":272,"acronym":273,"eligibilityCriteria":274,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":275,"targetDuration":4,"studyType":21,"phases":276,"briefSummary":277,"conditions":278,"keywords":281,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":285,"lastUpdatePostDateStruct":286,"startDateStruct":288,"completionDateStruct":290,"leadSponsor":292,"locationsCount":81},"100589950","phase-1-parathyroid-allotransplant-for-treatment-of-hypoparathyroidism-100589950","NCT06961071","Parathyroid Allotransplant for Treatment of Hypoparathyroidism","Parathyroid Allotransplant for Treatment of Hypoparathyroidism: PATTH","PATTH","Inclusion Criteria Only subjects who meet all of the following criteria are eligible for enrollment.\n\n1. Subjects age 18 or older.\n2. Subjects who are able to provide written informed consent and to comply with study procedures.\n3. Clinical history and laboratory data compatible with HypoPT as defined by hypocalcemia and documented PTH levels either inappropriately normal or below the normal range on two occasions greater than 2 weeks apart and 12 months after surgery, requiring treatment with activated vitamin D (≥0.5 mcg calcitrol) and oral calcium (≥800mg) daily, or currently on PTH (1-84), PTH (1-34), palopegteriparatide or other recombinant parathyroid hormone replacement injections with ongoing symptomatology due to hypocalcemia and variable degree of biochemical control.\n4. No history of immunodeficiency (e.g., opportunistic infections) that could be exacerbated by immunosuppression.\n5. Up to date immunizations per the University of California, San Francisco (UCSF) standard of care for organ transplantation, including influenza, pneumococcal, hepatitis B, and tetanus-diptheria\n\nExclusion Criteria Subjects who meet any of the following criteria are not eligible for enrollment\n\n1. Presence of donor specific anti-HLA antibodies detected by Luminex Single Antigen\u002Fspecificity bead assay including weakly reactive antibodies that would not be detected by a flow cross match\n2. Intolerance to any drug that will be used as part of the IS regimen.\n3. Poorly controlled diabetes with an A1C of \\>8%.\n4. Blood Pressure (BP): systolic blood pressure (SBP) \\> 140mmHg or DBP \\>90 mmHg despite treatment with antihypertensive agents. If the BP is greater than 140\u002F90 chart review and discussion with the patient will be done to establish that BP is in good control.\n5. Other exclusion criteria including significant renal or hepatic dysfunction\n6. For female subjects: Positive pregnancy test, presently breast-feeding, or unwillingness to use effective contraceptive measures for the duration of the study and 4 months after discontinuation. For male subjects: intent to procreate during the duration of the study or within 4 months after discontinuation or unwillingness to use effective measures of contraception. Oral contraceptives, Norplant®, Depo-Provera®, and barrier devices with spermicide are acceptable contraceptive methods; condoms used alone are not acceptable.\n7. Active infection including hepatitis B, hepatitis C, HIV, or tuberculosis (TB). Quantiferon gold assay will be used to determine TB infection.\n8. Invasive aspergillus, histoplasmosis, and coccidioidomycosis infection or other opportunistic infection within 1 year prior to study entry.\n9. Current malignancy or treated malignancy with estimated recurrence rate \\>50% at 5 years, except for completely resected squamous or basal cell carcinoma of the skin\n10. Known active alcohol or substance abuse.\n11. Active infections (except mild skin and nail fungal infections).\n12. Active peptic ulcer disease or gastritis, symptomatic gallstones, or portal hypertension.\n13. Use of any investigational agents within 4 weeks of screening or 5 half-lives of the investigational product\u002F medication, whichever is longer. Investigational products with prolonged invivo effects will require a wash-out period that aligns with the biochemical and physiologic effects of the agent prior to the initiation of this protocol. If the half life of the experimental agent is not known, participation in the study will be addressed with the study team and documented in the study record.\n14. Any investigational agents\u002Fproducts that could potentially interfere with the safety and\u002For efficacy of the procedure being studied will be addressed with the study team and documented in the study record.\n15. Administration of live attenuated vaccine(s) within 2 months of enrollment.\n16. Any medical condition that, in the opinion of the investigator, will interfere with safe study completion.\n17. Positive screen for polyoma (BK) viremia at time of screening.\n18. CKD stage 4 or 5\n19. Severe co-existing cardiac disease, characterized by any one of these conditions:\n\n    1. Recent myocardiol infarction (MI) (within 1 year)\n    2. Evidence of ischemia on functional cardiac exam within the last year. These include persantine thallium stress test and\u002For coronary angiogram which will be performed in any patient with a history of an MI\n    3. Left ventricular ejection fraction \\\u003C 45%\n    4. Valvular disease requiring replacement with prosthetic valve\n20. Substance use that in the opinion of the investigator would interfere with compliance with the study requirements.\n21. Past or current medical problems or findings from medical history, physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks from participation in the study, may interfere with the participant's ability to comply with study requirements or that may impact the quality or interpretation of the data obtained from the study.",{"count":203,"type":20},[236,121],"This study is being done to see if transplanting parathyroid tissue into the forearm will help hypo-parathyroid patients achieve parathyroid hormone (PTH) levels that would help normalize their serum calcium and phosphorus levels. The parathyroid tissue used in this study will come from cadaveric tissues that were donated at the time of the death of the donor(s).",[26,279,280],"Hypoparathyroidism Postprocedural","Hypoparathyroidism Post-surgical",[98,282,99,283,284],"parathyroid hormone","serum calcium","phosphorus","2026-02-24",{"date":287,"type":31},"2026-02-27",{"date":289,"type":31},"2026-01-15",{"date":291,"type":20},"2028-01-15",{"name":293,"class":80},"Peter Stock",{"id":295,"slug":296,"hasResults":11,"nctId":297,"briefTitle":298,"officialTitle":299,"acronym":300,"eligibilityCriteria":301,"healthyVolunteers":142,"sex":16,"minAge":17,"maxAge":143,"enrollmentInfo":302,"targetDuration":4,"studyType":146,"phases":4,"briefSummary":304,"conditions":305,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":313,"locationsCount":81},"100500253","hypoparathyroidism-natural-history-study-100500253","NCT05793853","Hypoparathyroidism Natural History Study","Advancing Product Development for Hypoparathyroidism: A Prospective Natural History Study of the Clinical Outcomes and Regulation of Disordered Mineral Metabolism","SHINE","Inclusion Criteria:\n\n* An understanding, ability and willingness to fully comply with study procedures and restrictions.\n* Ability to voluntarily provide written, signed and dated informed consent as applicable to participate in the study.\n* Male or female ≥18 years of age with HPT. All HPT sub-types are eligible, including surgical (HPT-S) and nonsurgical (HPT-NS) HPT: autoimmune, genetic (including but not limited to: DiGeorge syndrome, autoimmune polyendocrine syndrome type 1, hypoparathyroidism sensorineural deafness and renal disease syndrome, Kearns-Sayre syndrome, mitochondrial encephalomyopathy with lactic acidosis and stroke-like episodes \\[MELAS\\] syndrome, mitochondrial trifunctional protein \\[MTP\\] deficiency syndrome, Kenny-Caffey syndrome, Sanjad-Sakati syndrome, autosomal dominant hypocalcemia), infiltrative (granulomatous), mineral deposition (copper, iron), metastatic, radiation and idiopathic HPT.\n* Diagnosis of HPT established based on historic hypocalcemia in the setting of inappropriately low serum PTH levels on two occasions.\n* All treatment regimens are permitted, including but not limited to conventional management with calcium (e.g. calcium citrate, calcium carbonate, etc), active vitamin D (calcitriol, alfacalcidol), parent vitamin D, magnesium, phosphate binders and thiazides. Use of PTH-like drugs are permitted.\n\nExclusion Criteria:\n\n* Functional HPT\n* Transient HPT\n* Pseudohypoparathyroidism\n* Pregnancy",{"count":303,"type":20},106,"This is a prospective three-year natural history study of adults with hypoparathyroidism. The goal is to monitor patients with hypoparathyroidism to define end-organ damage in the context of the disease.\n\nThe study objectives are to:\n\n1. Build a prospective cohort of patients to study HPT-associated end-organ damage.\n2. Determine end-organ physiologic consequences of HPT.\n3. Elucidate determinants of HPT-associated end-organ damage.\n\nFunding Source - FDA OOPD",[26],"2025-12-08",{"date":308,"type":31},"2025-12-16",{"date":310,"type":31},"2022-08-25",{"date":312,"type":20},"2026-12",{"name":314,"class":80},"Columbia University",{"id":316,"slug":317,"hasResults":11,"nctId":318,"briefTitle":319,"officialTitle":320,"acronym":321,"eligibilityCriteria":322,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":323,"enrollmentInfo":324,"targetDuration":4,"studyType":146,"phases":4,"briefSummary":326,"conditions":327,"keywords":328,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":331,"lastUpdatePostDateStruct":332,"startDateStruct":334,"completionDateStruct":336,"leadSponsor":338,"locationsCount":4},"100605271","translation-and-validation-of-the-hypoparathyroidism-patient-experience-scales-hpes-questionnaire-in-greek-100605271","NCT07160348","Translation and Validation of the Hypoparathyroidism Patient Experience Scales (HPES) Questionnaire in Greek","Translation and Validation of the Hypoparathyroidism Patient Experience Scales (HPES) Questionnaire in Patients With Hypoparathyroidism for Use in the Greek Population","HPES","Inclusion Criteria:\n\nPatients should be ≥18 years of age, fluent in Greek language, diagnosed with chronic HP, on optimal treatment with calcium and active vitamin D metabolites. Chronic HP is defined when continuous therapy with calcium and vitamin D is required for \\>12 months.\n\nExclusion Criteria:\n\n1. Patients inadequately controlled with conventional therapy:\n\n   1. corrected serum Ca (cCa) ≤8 mg\u002Fdl or cCa ≤8.2 mg\u002Fdl with symptoms of hypocalcemia\n   2. serum P \\>5.5 mg\u002Fdl\n2. Age \\>80 years\n3. Presence of neoplastic disease\n4. Pregnancy\n5. Diagnosis of psychiatric disease or cognitive impairment\n6. Participants experiencing other comorbidities that may affect QoL\n7. Lack of informed consent","80 Years",{"count":325,"type":20},200,"This is a crossectional study that will be conducted at several tertiary centers in Greece.\n\nTo participate in the study, patients should be ≥18 years of age, fluent in Greek language, diagnosed with chronic HP, on optimal treatment with calcium and active vitamin D metabolites. Chronic HP is defined when continuous therapy with calcium and vitamin D is required for \\>12 months.\n\nExclusion criteria will include:\n\n1. Patients inadequately controlled with conventional therapy:\n\n   1. corrected serum Ca (cCa) ≤8 mg\u002Fdl or cCa ≤8.2 mg\u002Fdl with symptoms of hypocalcemia\n   2. serum P \\>5.5 mg\u002Fdl\n2. Age \\>80 years\n3. Presence of neoplastic disease\n4. Pregnancy\n5. Diagnosis of psychiatric disease or cognitive impairment\n6. Participants experiencing other comorbidities that may affect QoL\n7. Lack of informed consent The study will seek approval from the Ethics in Research Committee of its participating center. All participants will be informed about the objectives of the study and will sign an informed consent.\n\nThe HPES-Symptom was developed in accordance with the Food and Drug Administration guidance and best research practices for PRO measure development. The methodology used has been previously described.\n\nThe first step of the translation process requires two forward translations of the English version of the questionnaire. The translations will be done by two translators who are native speakers of the target (Greek) language and can understand the English version. Then a reconciled translation is made based on the two translations - that is, the chief investigator will review the two translations to achieve the best possible version by choosing one of the two translations or by combining them on the basis of their correctness, wording etc.\n\nThe next step requires translating the reconciled version back into English, again done by two translators who will be native speakers of English or at least will have a very good command of English.",[26],[98,282,329,330],"palopegteriparatide","calcium metabolism disorders","2025-08-29",{"date":333,"type":31},"2025-09-08",{"date":335,"type":20},"2025-10-01",{"date":337,"type":20},"2026-04-01",{"name":339,"class":80},"Aristotle University Of Thessaloniki",{"id":341,"slug":342,"hasResults":11,"nctId":343,"briefTitle":344,"officialTitle":345,"acronym":4,"eligibilityCriteria":346,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":347,"targetDuration":4,"studyType":21,"phases":349,"briefSummary":350,"conditions":351,"keywords":352,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":356,"lastUpdatePostDateStruct":357,"startDateStruct":359,"completionDateStruct":361,"leadSponsor":363,"locationsCount":365},"100558133","phase-2-evaluating-the-safety-and-efficacy-of-amor-1-as-a-treatment-for-hypocalcemia-associated-with-hypoparathyroidism-in-adults-100558133","NCT06547151","Evaluating the Safety and Efficacy of AMOR-1 as a Treatment for Hypocalcemia Associated With Hypoparathyroidism in Adults","A Phase 2, Prospective, Multinational, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of AMOR-1 as a Treatment of Hypocalcemia Associated With Hypoparathyroidism by Replacement of Currently Used Calcium Supplements (CS) in Adults.","Inclusion Criteria:\n\n1. An understanding, ability, and willingness to fully comply with study procedures and restrictions.\n2. Ability to voluntarily provide written, signed, and dated informed consent as applicable to participants in the study.\n3. Adult males or females 18 or older (prior to screening). Those \\\u003C 25 years old will be examined radiologically (Bone age X-ray of non-dominant wrist and hand) to ensure epiphyseal closure prior to enrollment into the study.\n4. Hypoparathyroidism patients, from any etiology, who are on currently available Standard of Care (SoC) e.g., calcium supplement and active vitamin D metabolite\u002Fanalog.\n5. Oral calcium ≥ 1000 mg QD above the normal dietary calcium intake\n6. Albumin-adjusted total serum calcium concentration level between 7.5 mg\u002FdL and 10.5 mg\u002FdL, or if outside of this range, considered not clinically significant by the Investigator.\n7. Vitamin D metabolite\u002Fanalog therapy with calcitriol ≥0.25μg QD or alfacalcidol ≥0.50 μg QD.\n8. Serum 25-hydroxyvitamin D (25OHD) ≥50 nmol\u002Fl (20 ng\u002Fml), or if below, considered not clinically significant by the Investigator.\n9. No change of treatment for hypocalcemia over the last 3 months prior to Screening as reported by the patient or through medical documentation, or if a change has occurred, it is expected to remain stable, as determined by the Investigator.\n10. Absence or stable symptoms from hypocalcemia over the last 3 months prior to Screening as reported by the patient or through medical documentation.\n11. For subjects receiving thyroid replacement therapy, the dose is stable for at least 6 weeks prior to screening and the TSH serum levels are within the normal range. A serum TSH level below the lower limit of the normal range but not undetectable in participant treated with thyroid hormone may be allowed if there is no anticipated need for a change in thyroid hormone dose during the trial.\n12. Female subjects who are postmenopausal (12 consecutive months of spontaneous amenorrhea and age \\>= 51 years), or who are surgically sterilized may be enrolled, as may women of childbearing potential who had a negative pregnancy test at screening and are willing to use two medically acceptable methods of contraception for the duration of the study and undergo pregnancy testing according to the study protocol.\n\nExclusion Criteria:\n\n1. Any disease that might affect calcium metabolism or calcium-phosphate homeostasis other than hypoparathyroidism, such as active hyperthyroidism, Paget's disease of bone, Type 1 or poorly controlled Type 2 diabetes mellitus (HbA1c \\> 9%), acromegaly, multiple endocrine neoplasia types I and II, Cushing's syndrome or disease, acute pancreatitis, malnutrition, recent prolonged immobility.\n2. Severe liver disease (Child-Pugh score \\>9) (US FDA, 2003) or hepatic transaminases (ALT and AST) \\> 3 times the upper limit.\n3. Severe renal insufficiency defined as estimated glomerular filtration rate (eGFR) \\\u003C 30 ml\u002Fmin\u002F1.73 m2.\n4. Clinical history of symptomatic renal stones within the past 3 months. Subjects with asymptomatic renal stones are permitted.\n5. Poorly controlled short bowel syndrome, bowel resection, tropical sprue, celiac disease, ulcerative colitis, and Crohn's disease.\n6. Chronic or severe cardiac disease within the past 6 months including but not limited to heart failure classified as NYHA Class II-IV (Dolgin and NYHA, 1994), uncontrolled arrhythmias, bradycardia (resting heart rate \\\u003C 48 beats\u002Fminute), QTc \\>450msec (males) or \\>470 msec (females) on ECG.\n7. History of active or untreated malignancy (excluding thyroid cancer or basal cell skin cancer) within the past 2 years. For thyroid cancers, low-risk well-differentiated thyroid cancer that is stable does not require a disease-free period. High-risk thyroid cancer or uncontrolled cases must be disease-free for at least 1 year prior to Screening.\n8. Seizure disorder\u002Fepilepsy with a history of a seizure within the previous 6 months prior to screening.\n9. Acute gout within 6 months prior to screening.\n10. Cerebrovascular accident within 6 months prior to Screening.\n11. Subjects dependent on regular parenteral calcium infusions (e.g., calcium gluconate) to maintain calcium homeostasis.\n12. Use of prohibited medications within respective prohibited periods prior to screening such as loop diuretics (30 days), raloxifene hydrochloride (3 months), lithium (30 days), methotrexate at dose \\>20 mg per week, or systemic corticosteroids (3 months).\n13. Thiazide diuretics may be permitted if the dosage has remained stable for three months prior to screening, and there is no expected need for a dosage change during the trial.\n14. Other drugs known to influence calcium and bone metabolism, such as calcitonin, cinacalcet hydrochloride, and fluoride tablets within 3 months prior to screening.\n15. Use of oral bisphosphonates within 6 months or IV bisphosphonate preparations within 12 months prior to screening.\n16. Previous treatment with PTH\u002Fparathyroid hormone-related protein-like drugs, including PTH(1-84) and PTH(1-34) within 30 days prior to screening.\n17. Current use of Amorphous Calcium Carbonate (ACC) food supplement.\n18. History of diagnosed substance abuse or alcohol dependence within the previous 3 years.\n19. Pregnant\u002F breastfeeding patients.",{"count":348,"type":20},81,[121],"This clinical trial aims to evaluate the efficacy and safety of AMOR-1, consisting of Amorphous Calcium Carbonate (ACC) as the active drug substance, in treating hypocalcemia in adults with hypoparathyroidism.",[26],[353,98,354,53,355],"Amorphous Calcium Carbonate","Hypopara","Calcium Carbonate","2025-08-28",{"date":358,"type":31},"2025-09-04",{"date":360,"type":31},"2024-12-15",{"date":362,"type":20},"2026-09",{"name":364,"class":38},"Amorphical Ltd.",8,{"id":367,"slug":368,"hasResults":11,"nctId":369,"briefTitle":370,"officialTitle":370,"acronym":371,"eligibilityCriteria":372,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":373,"targetDuration":4,"studyType":21,"phases":375,"briefSummary":376,"conditions":377,"keywords":4,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":378,"lastUpdatePostDateStruct":379,"startDateStruct":381,"completionDateStruct":383,"leadSponsor":385,"locationsCount":81},"100448094","parathyroid-allotransplantation-in-medically-refractory-hypoparathyroidism-100448094","NCT05114980","Parathyroid Allotransplantation in Medically Refractory Hypoparathyroidism","PATH","Inclusion Criteria:\n\n* Individual diagnosed with hypocalcemia secondary to\n\n  1. Hypoparathyroidism:\n\n     1. Prior anterior cervical neck surgery resulting in hypoparathyroidism\n     2. Congenital absence or malformation of parathyroid glands during development\n  2. Presence of hypoparathyroidism for at least one year\n  3. Failure of medical treatment for hypocalcemia, including need for IV calcium, with negative impact on quality of life and daily function\n  4. Age 18-80 years\n  5. Lives in the greater Birmingham region for the duration of the trial\n  6. Fluent in the English Language\n  7. Willing to comply with screening, protocol and all required procedures\n\nExclusion Criteria:\n\n1. Any active malignancy, except non-melanoma skin cancer\n2. Dependence on nursing home or other long-term care provider\n3. History of ischemic cardiomyopathy with ejection fraction \\\u003C20%, uncontrolled diabetes mellitus (Hgb A1c \\>10), thrombophilia or other clotting or bleeding disorders, significant heart, liver, kidney or central nervous system disease\n4. History of significant psychiatric illness\n5. Severe osteoporosis\n6. Allergy, hypersensitivity, or intolerance of expected immunosuppressive agents (i.e. Thymoglobulin®, tacrolimus, etc.)\n7. Documented history of gross non-adherence to medical therapies\n8. Significant functional\u002Fcognitive impairment without reliable caregiver\n9. Presence of active documented systemic infection or recent systemic infection within the past 3 months\n10. Seropositivity for HIV, HBV core antibody or antigen, HCV, HTLV-1\n11. Current smoker (smoking cessation must have occurred 3 months prior to enrollment)\n12. Chemical and\u002For alcohol dependency or abuse\n13. Psychosocial problems (including alcoholism, drug abuse, documented behavioral disorders)\n14. Resources deemed inadequate to support necessary post-transplant care",{"count":374,"type":20},5,[50],"Options for treatment of severe, refractory hypocalcemia are limited for the thousands of patients in the United States who suffer from hypoparathyroidism. Parathyroid allotransplantation is an emerging treatment that provides hope for these individuals. Currently, this therapy has only been successfully provided by a few centers in the world. In the UAB PATH trial, we propose to become one of the few centers worldwide to successfully achieve parathyroid allotransplantation in transplant-naïve patients.",[26],"2025-07-08",{"date":380,"type":31},"2025-07-11",{"date":382,"type":20},"2027-07",{"date":384,"type":20},"2030-01",{"name":386,"class":80},"University of Alabama at Birmingham",{"id":388,"slug":389,"hasResults":11,"nctId":390,"briefTitle":391,"officialTitle":392,"acronym":4,"eligibilityCriteria":393,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":90,"enrollmentInfo":394,"targetDuration":4,"studyType":21,"phases":396,"briefSummary":397,"conditions":398,"keywords":399,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":401,"lastUpdatePostDateStruct":402,"startDateStruct":404,"completionDateStruct":406,"leadSponsor":408,"locationsCount":81},"100592072","phase-2-a-phase-2-trial-investigating-the-safety-tolerability-and-efficacy-of-ext608-in-adults-with-hypoparathyroidism-100592072","NCT06988670","A Phase 2 Trial Investigating the Safety, Tolerability and Efficacy of EXT608 in Adults With Hypoparathyroidism","A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Trial Investigating the Safety, Tolerability and Efficacy of EXT608 in Adults With Hypoparathyroidism","Inclusion Criteria:\n\n1. Ability to personally provide written, signed, and dated informed consent to participate in the study.\n2. An understanding, ability, and willingness to fully comply with study procedures and restrictions.\n3. Male or female between 18 and 65 years of age. Male participants with female partners of child bearing potential must agree to use barrier contraception, e.g., condoms plus spermicide, from administration of the study drug until at least 3 months after administration of the study drug. Abstinence from heterosexual intercourse from administration of study drug until at least 3 months after administration of study drug is acceptable if it is in accordance with the participant's lifestyle. Female participants should be either surgically sterile (had a bilateral tubal ligation, bilateral salpingectomy, bilateral oophorectomy, or hysterectomy), postmenopausal (defined as 12 months with no menses prior to screening and a serum follicle stimulating hormone in the postmenopausal range at screening), or, if of child bearing potential, must be non-lactating and willing to use a highly effective method of birth control for 30 days prior to administration of study drug and agree to continued use of this method until at least 3 months after administration of study drug.\n4. Participants have a history of hypoparathyroidism for 12 months at least, with PTH levels below the LLN with concomitant serum calcium \\\u003C 9 mg\u002FdL.\n5. Participants are treated with a daily dose \\> 750 mg elemental calcium if using \\> 0.25 µg\u002Fday calcitriol, or a daily dose \\> 1000 mg elemental calcium if not using calcitriol.\n6. Participants have normal blood levels of 25-hydroxyvitamin D (i.e. \\> 20 ng\u002FdL or \\> 75 nmol\u002FL) and not above 1.5 times the upper limit of normal.\n7. Participants have normal thyroid test results for 3 months at least while taking a stable dose of thyroid medication or no medication.\n8. Participants have a BMI \\\u003C 35 kg\u002Fm2.\n9. Albumin-adjusted serum calcium level should be between the lower half and the middle of the normal range upon randomization into the study.\n\nExclusion Criteria:\n\n1. Participants with hypoparathyroidism due to an activating mutation of the calcium sensing receptor, pseudohypoparathyroidism, any non-hypoparathyroidism disease that may affect calcium metabolism or phosphor-calcium homeostasis, or requiring parenteral calcium infusions.\n2. Unwillingness to use a diary deployed on a smartphone daily for recording vitamin D, active vitamin D, calcium, magnesium and study drug doses as well as periodic symptom reporting.\n3. Participants with a history of neoplasia (except thyroid cancer) with no sign of recurrence 5 years after diagnosis.\n4. Participants with a history of or active GI tract disease that may impact the absorption of calcium (e.g. malabsorption).\n5. Participants with a history of severe hypocalcemia leading to seizures or cardiac arrhythmias within 6 months prior to screening.\n6. Participants with chronic kidney disease (eGFR \\\u003C 30 ml\u002Fmin) or active nephrolithiasis (needing pain medication in the last 6 months).\n7. Participants taking the following medications within the respective exclusion period:\n\n   * Proton pump inhibitors (4 weeks)\n   * Bisphosphonates (3 months)\n   * Parathyroid hormone, PTH analogs (6 months)\n   * Thiazide diuretics (14 days)\n   * Calcitonin or calcinet hydrochloride (3 months)\n8. Participant has increased CV proarrhythmic potential:\n\n   1. Participant has a QT interval with Fridericia's correction method (QTcF) \\>450 ms or PR outside the range of 120 to 220 ms, confirmed with one repeat testing, at the Screening Visit or Inpatient Check-in (Day -1) Visit.\n   2. A history of additional risk factors for TdP (e.g., heart failure, hypokalemia, family history of Long QT Syndrome).\n   3. The use of concomitant medications that prolong the QT\u002FQTc interval.\n9. Chronic\u002Fsevere cardiac disease including, but not limited to, cardiac insufficiency, unstable angina, arrhythmias, bradycardia (resting heart rate \\\u003C60 beats\u002Fminute), or hypotension (systolic and diastolic blood pressures \\\u003C100 and 60 mmHg, respectively).\n10. Any condition or disease that, in the opinion of the investigator, may interfere with a participant's participation or may confound the interpretation of safety or efficacy in the study.",{"count":395,"type":20},35,[121],"The goal of this clinical trial is to investigate the safety, tolerability and efficacy of EXT608 in adults with hypoparathyroidism.",[26],[400],"hypopara","2025-05-21",{"date":403,"type":31},"2025-05-25",{"date":405,"type":31},"2025-05-05",{"date":407,"type":20},"2027-05",{"name":409,"class":38},"Extend Biosciences Inc.",{"id":411,"slug":412,"hasResults":11,"nctId":413,"briefTitle":414,"officialTitle":414,"acronym":415,"eligibilityCriteria":416,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":417,"targetDuration":419,"studyType":146,"phases":4,"briefSummary":420,"conditions":421,"keywords":423,"overallStatus":71,"whyStopped":4,"lastUpdateSubmitDate":427,"lastUpdatePostDateStruct":428,"startDateStruct":430,"completionDateStruct":432,"leadSponsor":434,"locationsCount":81},"100550281","tunisian-clinical-registry-on-hypoparathyroidism-and-pseudo-hypoparathyroidism-100550281","NCT06445036","Tunisian Clinical Registry on Hypoparathyroidism and Pseudo-hypoparathyroidism","THYPARS","Inclusion Criteria:\n\n* Hypoparathyroidism defined by low serum calcium \\\u003C 2.2 mmol\u002Fl (\\\u003C 88 mg\u002Fl) associated with inadequate PTH (low or normal) and normal creatinine\n\nExclusion Criteria:\n\n* Cervical surgery \\\u003C 6 months.\n* Transient (neonatal, etc.) or functional (dysmagnesemia, etc.) hypoparathyroidism.\n* Other causes of hypocalcemia: vitamin D deficiency, chronic renal failure, etc.\n* Familial hypocalcemia hypercalciuria.\n* Pseudo-pseudo-hypoparathyroidism.",{"count":418,"type":20},1000,"1 Day","Observational, multicenter, national, cross-sectional study aiming to describe the epidemiological clinical, biological and therapeutic profile of patients suffering from defect in secretion (hypoparathyroidism) or action (pseudo-hypoparathyroidism) of parathyroid hormone.",[26,422],"Pseudo Hypoparathyroidism",[26,422,424,425,426],"Clinical Registry","Endocrinology","Parathyroid gland","2025-02-20",{"date":429,"type":31},"2025-02-21",{"date":431,"type":20},"2025-02-27",{"date":433,"type":20},"2025-07-27",{"name":435,"class":80},"Dacima Consulting",{"id":437,"slug":438,"hasResults":11,"nctId":439,"briefTitle":440,"officialTitle":440,"acronym":4,"eligibilityCriteria":441,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":442,"targetDuration":444,"studyType":146,"phases":4,"briefSummary":445,"conditions":446,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":447,"lastUpdatePostDateStruct":448,"startDateStruct":450,"completionDateStruct":452,"leadSponsor":454,"locationsCount":81},"100577410","establishment-of-a-registry-of-patients-with-parathyroid-disease-100577410","NCT06797934","Establishment of a Registry of Patients With Parathyroid Disease","Inclusion Criteria:\n\n* Age ≥18 years\n* Diagnosis of hyperparathyroidism or hypoparathyroidism based on biochemical parameters (calcemia, parathormone, phosphormia, creatinine, albumin, vitamin D25OH)\n* Obtaining informed consent\n\nExclusion Criteria:\n\n* none",{"count":443,"type":20},1200,"10 Years","Establishment of a registry with which to census all patients under the care of the O.U. Endocrinology for parathyroid pathology in order to longitudinally evaluate biochemical, clinical, radiological, medico-nuclear and histological data in future studies.",[156,26],"2025-01-22",{"date":449,"type":31},"2025-01-29",{"date":451,"type":31},"2022-01-03",{"date":453,"type":20},"2039-12-31",{"name":455,"class":80},"IRCCS Azienda Ospedaliero-Universitaria di Bologna",{"id":457,"slug":458,"hasResults":11,"nctId":459,"briefTitle":460,"officialTitle":461,"acronym":4,"eligibilityCriteria":462,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":463,"targetDuration":444,"studyType":146,"phases":4,"briefSummary":465,"conditions":466,"keywords":467,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":471,"lastUpdatePostDateStruct":472,"startDateStruct":474,"completionDateStruct":476,"leadSponsor":478,"locationsCount":480},"100565724","institution-of-an-italian-multicenter-database-of-patients-affected-by-hypoparathyroidism-or-pseudohypoparathyroidism-100565724","NCT06645899","Institution of an Italian Multicenter Database of Patients Affected by Hypoparathyroidism or Pseudohypoparathyroidism","Creation, Management and Analysis of a National Database of Patients Affected by Hypoparathyroidism or Pseudohypoparathyroidism","Inclusion Criteria:\n\n* Cohort 1: chronic hypoparathyroidism (all etiological forms)\n* Cohort 2: pseudohypoparathyroidism\n\nExclusion Criteria:\n\n* None",{"count":464,"type":20},600,"The goal of this observational study is to create, manage and analyze a multicenter national database of patients affected by hypoparathyroidism or pseudohypoparathyroidism, aimed at collecting and studying anamnestic, diagnostic, genetic, clinical, and therapeutic data in a relatively wide number of patients with these two rare pathologies, in Italy.\n\nThe study will include 41 specialist clinical centers of endocrinology, pediatric endocrinology, pediatrics, and endocrine surgery, located throughout the Italian territory, and to which patients refer from all the 20 regions of Italy.\n\nData will be collected over time, both in retrospective and prospective manners, during the 10-year duration of the study, starting from the recruiting visit (basal visit) and then during each follow-up visits patients will undergo for the control of disease at the recruiting clinical centers.\n\nCollected data will include both the most classic traits of the pathology and the less common ones, with the final goal of refining and deepening medical knowledge in the field of these two clinical conditions affecting parathyroid function and calcium homeostasis, and, thus, to be able to define optimal clinical and therapeutic management of patients, improving their quality of life.\n\nThe main aspects this observational study aims to assess and clarify are:\n\n1. Evaluation of prevalence and incidence of hypoparathyroidism, globally and in its different etiological forms, and of pseudohypoparathyroidism in Italy.\n2. Clinical characterization of different etiological forms of hypoparathyroidism, through both cross-sectional and longitudinal analyses of collected data.\n3. Clinical characterization of pseudohypoparathyroidism, through both cross-sectional and longitudinal analyses of collected data.\n4. Over time collection of data on bone status and bone fragility in patients with hypoparathyroidism and pseudohypoparathyroidism, to evaluate the prevalence and incidence of fragility fractures in these patients, globally and also based on gender, age, and disease etiology.\n5. Over time evaluation of response to pharmacological therapies in patients with hypoparathyroidism and pseudohypoparathyroidism The study will include two independent cohorts of female and male patients of any age, one including patients with chronic hypoparathyroidism of each etiological forms (cohort 1), and one including patients with pseudohypoparathyroidism (cohort 2). The study does not include either any control group\u002Fcomparison group or healthy volunteers.\n\nThe study itself does not involve any medical intervention or drug administration. Pharmacological treatments for which data on response to therapy will be collected in the database, are those administered to patients for the control\u002Ftreatment of hypoparathyroidism or pseudohypoparathyroidism, regardless of their inclusion in this observational study.",[26,422],[26,468,469,470],"Pseudohypoparathyroidism","Database of patients","Retro-prospective clinical data collection","2025-01-21",{"date":473,"type":31},"2025-01-23",{"date":475,"type":31},"2024-11-04",{"date":477,"type":20},"2034-11-04",{"name":479,"class":80},"F.I.R.M.O. - Fondazione Italiana Ricerca sulle Malattie dell'Osso - Ente del Terzo Settore",41,{"id":482,"slug":483,"hasResults":11,"nctId":484,"briefTitle":485,"officialTitle":486,"acronym":487,"eligibilityCriteria":488,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":489,"targetDuration":491,"studyType":146,"phases":4,"briefSummary":492,"conditions":493,"keywords":494,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":497,"lastUpdatePostDateStruct":498,"startDateStruct":500,"completionDateStruct":502,"leadSponsor":504,"locationsCount":506},"100273416","survey-on-epidemiology-of-hypoparathyroidism-in-france-100273416","NCT02838927","Survey on Epidemiology of Hypoparathyroidism in France","Epi-Hypo: Survey on Epidemiology of Hypoparathyroidism in France","Epi-Hypo","Inclusion Criteria:\n\n* patient fro whom chronic hypoparathyroidism is diagnosed\n* patient living in France\n\nExclusion Criteria:\n\n* patient who does not want his data to be collected in this registry\n* pseudo-hypoparathyroidism\n* acute hypoparathyroidism",{"count":490,"type":20},3000,"20 Years","Very few data has been published on the epidemiology of hypoparathyroidism worldwide: none exists specifically for France. Hypoparathyroidism could led to complications. Here, the investigators plan to collect data about both epidemiology, medication and complication of hypoparathyroidism in France.",[26],[26,495,496],"Epidemiology","Medication Therapy Management","2024-09-22",{"date":499,"type":31},"2024-09-24",{"date":501,"type":31},"2016-07",{"date":503,"type":20},"2031-09",{"name":505,"class":80},"European Georges Pompidou Hospital",57]